Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$1.67
-$0.02(-0.88%)
At close: 4:00 PM EST
$1.67
-$0.02(-0.88%)
Day’s Range― - ―
52-Week Range$1.35 - $4.92
Previous CloseN/A
Volume58.22K
Average Volume (3M)207.96K
Market Cap
$16.34M
Enterprise Value$3.36M
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$15.00Price Target Upside798.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Asset & Mechanism (CCL24)Nebokitug’s Phase 2 SPRING biomarker and proteomic signals showing dose-dependent improvements and modulation of core fibrotic and immune pathways validate the CCL24 target biology. Durable scientific validation strengthens the clinical rationale, increases partner interest, and reduces program risk over the medium term.
Low Leverage / Minimal DebtVery low reported leverage reduces financial distress risk and preserves strategic optionality for a capital-intensive clinical-stage biotech. Minimal debt lowers fixed obligations and supports flexibility in structuring future financings or partnerships over the next several quarters.
Board Refresh Adds Business Development ExpertiseAdding a veteran biotech dealmaker to the board and strengthening independent committees improves governance and commercial/partnering credibility. Enhanced board expertise is a durable structural benefit for negotiating collaborations and guiding late-stage development and capital strategy.
Bears Say
Pre-revenue With Persistent Cash BurnChemomab remains pre-revenue with negative operating and free cash flow across years. Although cash burn improved in 2025, the company still depends on external capital. This persistent funding need raises dilution and execution risk if market access tightens over the medium term.
Eroding Equity And Negative ROESignificant declines in equity and total assets reflect sustained losses and cash depletion, producing strongly negative returns on equity. This structural erosion weakens balance-sheet resilience, can dilute existing shareholders with future financings, and impairs long-term financial flexibility.
Limited Shareholder EngagementAn adjourned AGM due to quorum shortfall signals weak shareholder engagement and potentially thin institutional support. Low engagement is a durable governance and capital-raising headwind that can complicate approvals, reduce market confidence, and raise execution risk for future financings.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.35 and its highest was $4.92 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $16.34M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 32 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -2.299%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$15.00
▲(798.20% Upside)
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---